<DOC>
	<DOC>NCT01568125</DOC>
	<brief_summary>It is well known that incretin, particular GLP-ï¼‘enhances satiety and reduces energy intake in controlling appetite and dietary in humans (Flint A, et al. Gutzwiller JP et al.). Recently, incretin-based therapy has been attracted a lot of interest (Hare KJ, Knop FK). However, it is not clear how the incretin-based therapy affects energy and content of dietary intake in patients with type 2 diabetes mellitus (T2DM). Previously, the investigators reported the amount of energy and content of dietary intake in type 2 diabetic Japanese patients with more than 10 years of long time duration after discovery using questionnaire (Inoue K et al.) and the patients were impaired a secretion of active GLP-1 (Kamoi et al). The investigators examine whether the incretin-based therapy effects on the energy and content of dietary intake in the same patients before and one year after administration of incretin-related drugs using the same method previously (Inoue K et al.).</brief_summary>
	<brief_title>Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Japanese patients with T2DM without incretinbased therapy, who participated to examine the energy and content of intake using questionnaire reported previously. Patients with a serious complication in the heart, liver or kidney Pregnant or possibly pregnant patients or lactating patients Patients complicated with a malignant tumor at present. Patients participating in other clinical study. Other than the above, patients judged inappropriate as the subjects of this study by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>